Feedback
Settings

Settings

Goto Application

11,472 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(DWRXFEITVBNRMK-JXOAFFINSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 1,148
1.WO/2025/257084LIPID COMPOSITION
WO - 18.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/EP2025/065927 Applicant ISAR BIOSCIENCE GMBH Inventor KLÜPFEL, Julia
The present invention relates to a lipid composition for lipid nanoparticles (LNP), which comprises: (a) one or more cationic and/or cationically ionizable lipids; (b) a sterol; (c) one or more helper lipids; and (d) a lipid obtainable by a method comprising (i) subjecting a mixture comprising one or more monomers of the following formula (I), (I) wherein R1 represents an ethyl group, R3 and R4, which may be the same or different, independently represent a hydrogen atom, or a C1-2 alkyl group, to cationic ring opening polymerization in the presence of a polymerization initiator for providing a linear polymer; and (ii) introducing a terminal group R2 of the following formula (II): (II) wherein k is an integer of 1 so that a spacer exists between the polyoxazoline chain and Z, whereby the structure of the spacer is determined by the repeating units y and z; y is 0 or an integer of 1 to 3, and z is 0 or an integer of 1 to 3; a which may be the same or different when more than one is present, represents an integer of 1 to 6; b represents 0 or an integer of 1 to 6; X1 which may be the same or different when more than one is present, independently represents an oxygen atom, a group -O-CO-, -N-CO-, or -NR' wherein R' is a hydrogen atom or an alkyl group; X2 which may be the same or different when more than one is present, represents a single bond or a group -CO-; X3 which may be the same or different when more than one is present, independently represents a single bond, an oxygen atom, a group - O-CO-, or -NR'' wherein R'' is a hydrogen atom or an alkyl group; Z represents a group -NRaRb, wherein Ra represents a C6-20 alkyl group; and Rb represents a hydrogen atom or a C6-20 alkyl group.
2.WO/2025/259607NOVEL BIOMARKER FOR DETERMINING PROGNOSIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO - 18.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/032884 Applicant AVIDITY BIOSCIENCES, INC. Inventor HALSETH, Amy Elizabeth
Disclosed herein is a novel biomarker for determining prognosis of facioscapulohumeral muscular dystrophy (FSHD).
3.WO/2025/259743DUAL CONJUGATE COMPOUNDS FOR EXTRAHEPATIC DELIVERY
WO - 18.12.2025
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2025/033130 Applicant ALNYLAM PHARMACEUTICALS, INC. Inventor NAIR, Jayaprakash, K.
The present disclosure provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; at least one alpha-v-beta-6 (αvβ6) integrin targeting ligand that mediates delivery to muscle tissue conjugated to at least one strand; and at least one in vivo delivery enhancing moiety conjugated to one or more internal positions on at least one strand. The present disclosure also provides compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a disorder that would benefit from reduction in expression of the target gene.
4.WO/2025/257329FUSION POLYPEPTIDE AND LIPONANOPARTICLE COMPRISING THE SAME
WO - 18.12.2025
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/EP2025/066426 Applicant STRIKE PHARMA AB Inventor MANGSBO, Sara
The present disclosure relates to fusion polypeptide comprising a tag moiety and a polypeptide comprising an apolipoprotein or a fragment thereof, for example for delivery of a loaded decorated liponanoparticle attached via the apolipoprotein or a fragment thereof to a cell of interest, wherein said loaded decorated liponanopaticle comprises a payload. Also disclosed are loaded decorated liponanoparticles comprising said fusion polypeptide and a complex comprising a bispecific binding molecule and the loaded decorated liponanoparticle. Medical uses of the fusion polypeptide, loaded decorated liponanoparticle and complex as disclosed herein are also provided.
5.WO/2025/260018PARTICLE DELIVERY FOR SELF-AMPLIFYING VACCINES
WO - 18.12.2025
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/US2025/033600 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor STEINMETZ, Nicole F.
A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.
6.20250375499IMMUNORECEPTOR INHIBITORY PROTEINS AND RELATED METHODS
US - 11.12.2025
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
 Appl.No 19036498 Applicant Flagship Pioneering Innovations VII, LLC Inventor Hozefa Saifuddin BANDUKWALA

Provided herein are, inter alia, immunoreceptor inhibitory proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunoreceptor inhibitory proteins and compositions. The immunoreceptor inhibitory proteins provided herein are useful in e.g., pharmaceutical compositions and methods of use, including e.g., in the treatments of pro-inflammatory (e.g., autoimmune) diseases.

7.20250375390Method of Lyophilisation
US - 11.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19298524 Applicant GlaxoSmithKline Biologicals SA Inventor Frédéric MATHOT

The present invention provides lyophilised pharmaceutical compositions and methods of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising nucleic acid and lipid carrier particles and methods of making said lyophilised pharmaceutical compositions. The provided lyophilised compositions have improved critical quality attributes (CQAs) and the provided methods prevent the need for a deep-freeze cold chain. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.

8.WO/2025/255393HERPES SIMPLEX VIRUS ANTIGEN BINDING AGENTS FOR MITIGATION OF HERPES SIMPLEX VIRUS ASSOCIATED DISEASE
WO - 11.12.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No PCT/US2025/032531 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor COHEN, Gary H.
Provided herein are compositions for the prevention and treatment of genital herpes, comprising antigen binding agents to herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, ribonucleic acids (RNAs) encoding these antigen binding agents, and methods of use thereof.
9.WO/2025/255168MODIFIED CAS12 GUIDES AND USES THEREOF
WO - 11.12.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/032145 Applicant PIONEER HI-BRED INTERNATIONAL, INC. Inventor MAY, Andrew Paul
Disclosed herein are compositions, kits methods related to improved Cas12 systems, specifically including Cas12 guide RNAs. In particular, the present disclosure provides insights and technologies relating to Cas12f systems.
10.WO/2025/255199ARGININOSUCCINATE SYNTHASE 1 AND ARGININOSUCCINATE LYASE POLYPEPTIDES AND POLYNUCLEOTIDES AND USES THEREOF
WO - 11.12.2025
Int.Class A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
 Appl.No PCT/US2025/032201 Applicant MODERNATX, INC. Inventor BRUNDAGE, Meghan
This disclosure relates to mRNA therapy for the treatment of citrullinemia type 1 (CTLN1) and related diseases, disorders or conditions. mRNAs for use in the invention, when administered in vivo, encode the argininosuccinate synthase 1 (ASS1) polypeptide. Also provided are related polypeptides for use in the invention. Polypeptide and mRNA therapies of the disclosure increase and/or restore deficient levels of ASS1 expression and/or activity in subjects. Polypeptides and mRNA therapies of the disclosure may be used in combination with argininosuccinate lyase polypeptides or mRNAs encoding the same.
# -